Focus: PharmaIN is a Bothell-based biotech focused on subcutaneous peptides and out-licensing, with a diversified portfolio spanning neurology, cardiovascular, infectious diseases, immunology, and oncology. The company generates ~$200M in annual revenue, heavily concentrated in mature generic and branded formulations.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow PharmaIN to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from PharmaIN's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Cornerstone revenue driver (41% of total); mature, high-volume generic with established market position but limited growth upside.
Help build intelligence for PharmaIN
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Branded lidocaine formulation on patent through 2031; second-largest revenue contributor facing material patent cliff in 7 years.
Post-LOE topical dermatology product with modest, commoditized revenue base.
Post-LOE aromatase inhibitor oncology drug; revenue stable but subject to generic pricing pressure.
Post-LOE anti-inflammatory for gout; modest, mature indication with limited expansion potential.
Post-LOE benzodiazepine with legacy indication in psychiatry/neurology; stable generic revenue.
Post-LOE topical corticosteroid with modest, commoditized revenue base.
Post-LOE high-potency topical corticosteroid with minimal differentiation in crowded market.
Post-LOE topical corticosteroid for psoriasis; small revenue base with no patent protection.
Branded torsemide with patent protection through 2033; modest revenue with delayed cliff vs. ZTLIDO but limited growth prospect.
798 discontinued, 359 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
No recent FDA warnings or warn-letter filings on record; active shortages in controlled substances (amphetamines, meperidine, technetium) suggest supply-chain exposure but not direct quality/compliance risk to PharmaIN's product slate.
+228 more products